For research use only. Not for therapeutic Use.
Levofloxacin（Cat No.:I000113）is a broad-spectrum antibiotic belonging to the fluoroquinolone class, effective against a variety of bacterial infections. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes crucial for DNA replication and repair. Levofloxacin is commonly prescribed for respiratory tract infections, urinary tract infections, and skin infections, among others. It exhibits excellent oral bioavailability and tissue penetration, making it suitable for both intravenous and oral administration. While generally well-tolerated, potential side effects include gastrointestinal disturbances, central nervous system effects, and, in rare cases, tendon rupture, necessitating careful use in certain populations.
| Catalog Number | I000113 |
| CAS Number | 100986-85-4 |
| Synonyms | (S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |
| Molecular Formula | C18H20FN3O4 |
| Purity | ≥95% |
| Target | Antibiotic |
| Solubility | DMSO 25 mg/mL; Water 11.2 mg/mL |
| Storage | Store at -20C |
| IUPAC Name | (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
| InChI | InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1 |
| InChIKey | GSDSWSVVBLHKDQ-JTQLQIEISA-N |
| SMILES | C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O |
| Reference | </br>1:Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients. Van/’t Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343-17. doi: 10.1128/AAC.00343-17. [Epub ahead of print] PMID: 28507117 </br>2:Electrocatalytic properties of N-doped graphite felt in electro-Fenton process and degradation mechanism of levofloxacin. Liu X, Yang D, Zhou Y, Zhang J, Luo L, Meng S, Chen S, Tan M, Li Z, Tang L.Chemosphere. 2017 May 6;182:306-315. doi: 10.1016/j.chemosphere.2017.05.035. [Epub ahead of print] PMID: 28501570 </br>3:Application of Deep Eutectic Solvents in Hybrid Molecularly Imprinted Polymers and Mesoporous Siliceous Material for Solid-Phase Extraction of Levofloxacin from Green Bean Extract. Li X, Row KH.Anal Sci. 2017;33(5):611-617. doi: 10.2116/analsci.33.611. PMID: 28496066 Free Article</br>4:<i>In Vitro</i> Resistance Selection in <i>Shigella flexneri</i> by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin. Allen GP, Harris KA.Antimicrob Agents Chemother. 2017 May 8. pii: AAC.00086-17. doi: 10.1128/AAC.00086-17. [Epub ahead of print] PMID: 28483960 </br>5:[Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of <i>Helicobacter pylori</i> as the rescue therapy: a meta analysis]. Zhang M, Chen CY, Wang XT, Lyu B.Zhonghua Nei Ke Za Zhi. 2017 May 1;56(5):368-374. doi: 10.3760/cma.j.issn.0578-1426.2017.05.013. Chinese. PMID: 28460509 </br>6:Easy-Assessment of Levofloxacin and Minocycline in Relevant Biomimetic Media by HPLC-UV Analysis. Matos AC, Pinto RV, Bettencourt AF.J Chromatogr Sci. 2017 Apr 24:1-9. doi: 10.1093/chromsci/bmx033. [Epub ahead of print] PMID: 28444354 </br>7:Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients. Zhang L, Hu P.Clin Interv Aging. 2017 Apr 12;12:673-678. doi: 10.2147/CIA.S127009. eCollection 2017. PMID: 28442897 Free PMC Article</br>8:Experimental study on the influence of low-frequency and low-intensity ultrasound on the permeability of the Mycobacterium smegmatis cytoderm and potentiation with levofloxacin. Dong Y, Su H, Jiang H, Zheng H, Du Y, Wu J, Li D.Ultrason Sonochem. 2017 Jul;37:1-8. doi: 10.1016/j.ultsonch.2016.12.024. Epub 2016 Dec 19. PMID: 28427611 </br>9:Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. Akdag Cayli Y, Sahin S, Buttini F, Balducci AG, Montanari S, Vural I, Oner L.Drug Dev Ind Pharm. 2017 Apr 27:1-12. doi: 10.1080/03639045.2017.1318902. [Epub ahead of print] PMID: 28420285 </br>10:Levofloxacin-Induced Acute Immune-Mediated Thrombocytopenia of Rapid-Onset. Shih AW, Lam AS, Warkentin TE.J Pharm Pract. 2017 Jan 1:897190017702306. doi: 10.1177/0897190017702306. [Epub ahead of print] PMID: 28403679 |
